^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mustargen (mechlorethamine)

    Associations
    News

    Trials

    Company:
    Recordati
    Drug class:
    Alkylating agent
    Related drugs:
    Associations
    News

    Trials

    Apply
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
    Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma (NCT00574496)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    09/27/2023
    Initiation :
    11/13/2007
    Primary completion :
    08/02/2022
    Completion :
    08/02/2022
    CD20 • HLA-DRB1 • HLA-B
    |
    gemcitabine • cyclophosphamide • ifosfamide • vincristine • vinorelbine tartrate • prednisone • melphalan • fludarabine IV • Matulane (procarbazine hydrochloride) • cyclosporine • Mustargen (mechlorethamine)
    SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (NCT04150042)
    Phase 1
    General Oncology, Inc.
    Recruiting
    Last update posted :
    04/25/2023
    Initiation :
    01/13/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2 • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • PALB2 mutation
    |
    carmustine • melphalan • Mustargen (mechlorethamine)